You have free access to this content

Metals and amyloid-β in Alzheimer's disease

  1. Christa J. Maynard1,2,
  2. Ashley I. Bush1,2,3,4,
  3. Colin L. Masters1,2,
  4. Roberto Cappai1,2,
  5. Qiao-Xin Li1,2,*

Article first published online: 24 MAY 2005

DOI: 10.1111/j.0959-9673.2005.00434.x

Issue

International Journal of Experimental Pathology

International Journal of Experimental Pathology

Volume 86, Issue 3, pages 147–159, June 2005

Additional Information

How to Cite

Maynard, C. J., Bush, A. I., Masters, C. L., Cappai, R. and Li, Q.-X. (2005), Metals and amyloid-β in Alzheimer's disease. International Journal of Experimental Pathology, 86: 147–159. doi: 10.1111/j.0959-9673.2005.00434.x

Author Information

  1. 1

    Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia,

  2. 2

    The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia,

  3. 3

    Laboratory for Oxidation Biology, Genetics and Ageing Research Unit, Massachusetts General Hospital, Charlestown, MA, USA, and

  4. 4

    Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA

* Qiao-Xin Li, PhD Department of Pathology The University of Melbourne Parkville Victoria 3010 Australia Tel.: +61 3 8344 5878; Fax: +61 3 8344 4004; E-mail: qiao@unimelb.edu.au

Publication History

  1. Issue published online: 24 MAY 2005
  2. Article first published online: 24 MAY 2005
  3. Received for publication: 28 February 2005 Accepted for publication: 28 February 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (210K)

References

  • Aksenov M.Y., Tucker H.M., Nair P. et al. (1998) The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease. J. Mol. Neurosci. 11, 151–164.
  • Aschner M. (1997) Manganese neurotoxicity and oxidative damage. In: Metal and Oxidative Damage in Neurological Disorders. pp. 77–93. (ed. M.Aschner). New York, USA: Plenum Press.
  • Atwood C.S., Moir R.D., Huang X. et al. (1998) Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273, 12817–12826.
  • Atwood C.S., Huang X., Moir R.D., Tanzi R.E., Bush A.I. (1999) Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met. Ions Biol. Syst. 36, 309–364.
  • Atwood C.S., Huang X., Khatri A. et al. (2000a) Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol. Biol. (Noisy-le-Grand) 46, 777–783.
  • Atwood C.S., Scarpa R.C., Huang X. et al. (2000b) Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75, 1219–1233.
    Direct Link:
  • Atwood C.S., Obrenovich M.E., Liu T. et al. (2003) Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res. Brain Res. Rev. 43, 1–16.
  • Atwood C.S., Perry G., Zeng H. et al. (2004) Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43, 560–568.
  • Barnham K.J., Ciccotosto G.D., Tickler A.K. et al. (2003a) Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278, 42959–42965.
  • Barnham K.J., McKinstry W.J., Multhaup G. et al. (2003b) Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J. Biol. Chem. 278, 17401–17407.
  • Barnham K.J., Haeffner F., Ciccotosto G.D. et al. (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J. 18, 1427–1429.
  • Bartzokis G., Beckson M., Hance D.B., Marx P., Foster J.A., Marder S.R. (1997) MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging 15, 29–35.
  • Basun H., Forssell L.G., Wetterberg L., Winblad B. (1991) Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J. Neural. Transm. Park Dis. Dement. Sect. 3, 231–258.
  • Bayer T.A., Schafer S., Simons A. et al. (2003) Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc. Natl Acad. Sci. USA 100, 14187–14192.
  • Bellingham S.A., Ciccotosto G.D., Needham E. et al. (2004a) Gene knockout amyloid precursor protein amyloid precursor-like protein-2 increases cellular copper levels primary mouse cort neurons embryonic fibroblasts. J. Neurochem. 91, 423–428.
    Direct Link:
  • Bellingham S.A., Lahiri D.K., Maloney B., La Fontaine S., Multhaup G., Camakaris J. (2004b) Copper depletion down-regulates expression of the Alzheimer's disease amyloid-{beta} precursor protein gene. J. Biol. Chem. 279, 20378–20386.
  • Bohnen N., Jolles J., Degenaar C.P. (1994) Levels of trace elements in blood in healthy aging subjects. Z. Gerontol. 27, 324–327.
  • Borchardt T., Camakaris J., Cappai R., Masters C.L., Beyreuther K., Multhaup G. (1999) Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem. J. 344 (Pt 2), 461–467.
  • Brown D.R., Hafiz. F., Glasssmith L.L. et al. (2000) Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J. 19, 1180–1186.
  • Bush A.I., Multhaup G., Moir R.D. et al. (1993) A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J. Biol. Chem. 268, 16109–16112.
  • Bush A.I., Pettingell W.H. Jr, Paradis M.D., Tanzi R.E. (1994a) Modulation of A beta adhesiveness and secretase site cleavage by zinc. J. Biol. Chem. 269, 12152–12158.
  • Bush A.I., Pettingell W.H., Multhaup G. et al. (1994b) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265, 1464–1467.
  • Bush A.I. (2000) Metals and neuroscience. Curr. Opin. Chem. Biol. 4, 184–191.
  • Bush A.I. (2003) The metallobiology of Alzheimer's disease. Trends Neurosci. 26, 207–214.
  • Callahan M.J., Lipinski W.J., Bian F., Durham R.A., Pack A., Walker L.C. (2001) Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158, 1173–1177.
  • Castellani R.J., Smith M.A., Nunomura A., Harris P.L., Perry G. (1999) Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic. Biol. Med. 26, 1508–1512.
  • Chan C.-W., Dharmarajan A., Atwood C.S. et al. (1999) Anti-apoptotic action of Alzheimer A-beta. Alzheimer's Reports 2, 1–6.
  • Cheng S.Y., Trombetta L.D. (2004) The induction of amyloid precursor protein and alpha-synuclein in rat hippocampal astrocytes by diethyldithiocarbamate and copper with or without glutathione. Toxicol. Lett. 146, 139–149.
  • Cherny R.A., Legg J.T., McLean C.A. et al. (1999) Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 274, 23223–23228.
  • Cherny R.A, Atwood C.S., Xilinas M.E. et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665–676.
  • Clements A., Allsop D., Walsh D.M., Williams C.H. (1996) Aggregation and metal-binding properties of mutant forms of the amyloid A beta peptide of Alzheimer's disease. J. Neurochem. 66, 740–747.
    Direct Link:
  • Connor J.R., Snyder B.S., Beard J.L., Fine R.E., Mufson E.J. (1992) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31, 327–335.
    Direct Link:
  • Connor J.R., Tucker P., Johnson M., Snyder B. (1993) Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease. Neurosci. Lett. 159, 88–90.
  • Cornett C.R., Markesbery W.R., Ehmann W.D. (1998) Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19, 339–345.
  • Cottrell D.A., Blakely E.L., Johnson M.A., Ince P.G., Turnbull D.M. (2001) Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57, 260–264.
  • Cuajungco M.P., Goldstein L.E., Nunomura A. et al. (2000) Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J. Biol. Chem. 275, 19439–19442.
  • Curtain C.C., Ali F., Volitakis I. et al. (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276, 20466–20473.
  • Curtain C.C., Ali F.E., Smith D.G., Bush A.I., Masters C.L., Barnham K.J. (2003) Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J. Biol. Chem. 278, 2977–2982.
  • Dahlgren K.N., Manelli A.M., Stine W.B. Jr, Baker L.K., Krafft G.A., LaDu M.J. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 277, 32046–32053.
  • Danscher G., Jensen K.B., Frederickson C.J. et al. (1997) Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J. Neurosci. Methods 76, 53–59.
  • Davis R.E., Miller S., Herrnstadt C. et al. (1997) Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 94, 4526–4531.
  • Deibel M.A., Ehmann W.D., Markesbery W.R. (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol. Sci. 143, 137–142.
  • Del Corso L., Pastine F., Protti M.A. et al. (2000) Blood zinc, copper and magnesium in aging. A study in healthy home-living elderly. Panminerva Med. 42, 273–277.
  • Dong J., Atwood C.S., Anderson V.E. et al. (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42, 2768–2773.
  • Drayer B., Burger P., Darwin R., Riederer S., Herfkens R., Johnson G.A. (1986) MRI of brain iron. Am. J. Roentgenol. 147, 103–110.
  • Duara R., Grady C., Haxby J. et al. (1986) Positron emission tomography in Alzheimer's disease. Neurology 36, 879–887.
  • Floyd R.A. (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222, 236–245.
    Direct Link:
  • Frederickson C.J., Rampy B.A., Reamy-Rampy S., Howell G.A. (1992) Distribution of histochemically reactive zinc in the forebrain of the rat. J. Chem. Neuroanat. 5, 521–530.
  • Frederickson C.J., Bush A.I. (2001) Synaptically released zinc: physiological functions and pathological effects. Biometals 14, 353–366.
  • Friedlich A.L., Lee J.Y., Van Groen T. et al. (2004) Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J. Neurosci. 24, 3453–3459.
  • Friguet B., Stadtman E.R., Szweda L.I. (1994) Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J. Biol. Chem. 269, 21639–21643.
  • Galeazzi L., Ronchi P., Franceschi C., Giunta S. (1999) In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1–42) through dityrosine bridge formation. Amyloid 6, 7–13.
  • Gonzalez C., Martin T., Cacho J. et al. (1999) Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur. J. Clin. Invest 29, 637–642.
    Direct Link:
  • Hartter D.E. & Barnea A. (1988a) Brain tissue accumulates 67copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. J. Biol. Chem. 263, 799–805.
  • Hartter D.E. & Barnea A. (1988b) Evidence for release of copper in the brain: depolarization-induced release of newly taken-up 67copper. Synapse 2, 412–415.
    Direct Link:
  • Hensley K., Maidt M.L.,Yu Z., Sang H., Markesbery W.R., Floyd R.A. (1998) Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J. Neurosci. 18, 8126–8132.
  • Hesse L., Beher D., Masters C.L., Multhaup G. (1994) The beta A4 amyloid precursor protein binding to copper. FEBS Lett. 349, 109–116.
  • Huang X., Atwood C.S., Hartshorn M.A. et al. (1999a) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609–7616.
  • Huang X., Cuajungco M.P., Atwood C.S. et al. (1999b) Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274, 37111–37116.
  • Huang X., Atwood C.S., Moir R.D. et al. (1997) Zinc-induced Alzheimer's Abeta1–40 aggregation is mediated by conformational factors. J. Biol. Chem. 272, 26464–26470.
  • Kapaki E., Zournas C., Kanias G., Zambelis T., Kakami A., Papageorgiou C. (1997) Essential trace element alterations in amyotrophic lateral sclerosis. J. Neurol. Sci. 147, 171–175.
  • Koo E.H., Park L., Selkoe D.J. (1993) Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc. Natl Acad. Sci. USA 90, 4748–4752.
  • Kuo Y.M., Webster S., Emmerling M.R., De Lima N., Roher A.E. (1998) Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta 1406, 291–298.
  • Lee J.Y., Mook-Jung I., Koh J.Y. (1999) Histochemically reactive zinc in plaques of the Swedish mutant beta- amyloid precursor protein transgenic mice. J. Neurosci. 19, RC10.
  • Lee J.Y., Cole T.B., Palmiter R.D., Suh S.W., Koh J.Y. (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl Acad. Sci. USA 99, 7705–7710.
  • Lee J.Y., Friedman J.E., Angel I., Kozak A., Koh J.-Y. (2004a) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2004.01.005
  • Lee J.Y., Kim J.H., Hong S.H. et al. (2004b) Estrogen decreases zinc transporter 3 expression and synaptic vesicle zinc levels in mouse brain. J. Biol. Chem. 279, 8602–8607.
  • Loeffler D.A., DeMaggio A.J., Juneau P.L. et al. (1994) Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis. Assoc. Disord. 8, 190–197.
  • Loeffler D.A., LeWitt P.A., Juneau P.L. et al. (1996) Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 738, 265–274.
  • Loske C., Gerdemann A., Schepl W. et al. (2000) Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur. J. Biochem. 267, 4171–4178.
    Direct Link:
  • Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47–52.
  • Lovell M.A., Xie C., Markesbery W.R. (1999) Protection against amyloid beta peptide toxicity by zinc. Brain Res. 823, 88–95.
  • Lue L.F., Kuo Y.M., Roher A.E. et al. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol 155, 853–862.
  • Luo Y., Sunderland T., Roth G.S., Wolozin B. (1996) Physiological levels of beta-amyloid peptide promote PC12 cell proliferation. Neurosci. Lett. 217, 125–128.
  • Martin W.R., Ye F.Q., Allen P.S. (1998) Increasing striatal iron content associated with normal aging. Mov. Disord. 13, 281–286.
    Direct Link:
  • Massie H.R., Aiello V.R., Iodice A.A. (1979) Changes with age in copper and superoxide dismutase levels in brains of C57BL/6J mice. Mech. Ageing Dev. 10, 93–99.
  • Maurer I., Zierz S., Moller H.J. (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging 21, 455–462.
  • Maynard C.J., Cappai R., Volitakis I. et al. (2002) Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 4, 4.
  • McGeer E.G., McGeer P.L., Harrop R., Akiyama H., Kamo H. (1990) Correlations of regional postmortem enzyme activities with premortem local glucose metabolic rates in Alzheimer's disease. J. Neurosci. Res. 27, 612–619.
    Direct Link:
  • McLean C.A., Cherny R.A., Fraser F.W. et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860–866.
    Direct Link:
  • Mielke R., Herholz K., Grond M., Kessler J., Heiss W.D. (1992) Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol. Aging 13, 93–98.
  • Mielke R., Schroder R., Fink G.R., Kessler J., Herholz K., Heiss W.D. (1996) Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. (Berl) 91, 174–179.
  • Misonou H., Morishima-Kawashima M., Ihara Y. (2000) Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry 39, 6951–6959.
  • Miura T., Suzuki K., Kohata N., Takeuchi H. (2000) Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry 39, 7024–7031.
  • Molina J.A., Jimenez-Jimenez, F.J., Aguilar M.V. et al. (1998) Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J. Neural. Transm. 105, 479–488.
  • Morita A., Kimura M., Itokawa Y. (1994) The effect of aging on the mineral status of female mice. Biol. Trace Elem. Res. 42, 165–177.
  • Mucke L., Masliah E., Yu G.Q. et al. (2000) High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058.
  • Nunomura A., Perry G., Pappolla M.A. et al. (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959–1964.
  • Oddo S., Caccamo A., Shepherd J.D. et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409–421.
  • Omar R.A., Chyan Y.J., Andorn A.C., Poeggeler B., Robakis N.K., Pappolla M.A. (1999) Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J. Alzheimers Dis. 1, 139–145.
  • Opazo C., Huang X., Cherny R.A. et al. (2002) Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 277, 40302–40308.
  • Palmblad M., Westlind-Danielsson A., Bergquist J. (2002) Oxidation of methionine 35 attenuates formation of amyloid beta-peptide 1–40 oligomers. J. Biol. Chem. 277, 19506–19510.
  • Paola D., Domenicotti C., Nitti M. et al. (2000) Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem. Biophys. Res. Commun. 268, 642–646.
  • Pappolla M.A., Omar R.A., Kim K.S., Robakis N.K. (1992) Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am. J. Pathol. 140, 621–628.
  • Pappolla M.A., Chyan Y.J., Omar R.A. et al. (1998) Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 152, 871–877.
  • Perry G., Cash A.D., Smith M.A. (2002a) Alzheimer disease and oxidative stress. J. Biomed. Biotechnol. 2, 120–123.
  • Perry G., Sayre L.M., Atwood C.S. et al. (2002b) The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16, 339–352.
  • Phinney A.L., Drisaldi B., Schmidt S.D. et al. (2003) In vivo reduction of amyloid-beta by a mutant copper transporter. Proc. Natl Acad. Sci. USA 100, 14193–14198.
  • Plantin L.-O., Lysing-Tunnell U., Kristensson K. (1987) Trace elements in the human central nervous system studied with neutron activation analysis. Biol. Trace Elem. Res. 13, 69–75.
  • Pratico D., Lee V.M., Trojanowski J.Q., Rokach J., Fitzgerald G.A. (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12, 1777–1783.
  • Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., FitzGerald G.A. (2000a) Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48, 809–812.
    Direct Link:
  • Pratico D., Iuliano L., Amerio G. et al. (2000b) Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann. Neurol. 48, 795–798.
    Direct Link:
  • Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21, 4183–4187.
  • Rae T.D., Schmidt P.J., Pufahl R.A., Culotta V.C., O'Halloran T.V. (1999) Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science 284, 805–808.
  • Rao K.S.J., Rao R.V., Shanmugavelu P., Menon R.B. (1999) Trace elements in Alzheimer's disease brain: a new hypothesis. Alzheimer's Reports 2, 241–246.
  • Ritchie C.W., Bush A.I., Mackinnon A. et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685–1691.
  • Rogers J.T., Randall J.D., Cahill C.M. et al. (2002) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45518–45528.
  • Rottkamp C.A., Raina A.K., Zhu X. et al. (2001) Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 30, 447–450.
  • Samokyszyn V.M., Reif D.W., Miller D.M., Aust. S.D. (1991) Effects of ceruloplasmin on superoxide-dependent iron release from ferritin and lipid peroxidation. Free Radic. Res. Commun. 12-13 (Pt 1), 153–159.
  • Samudralwar D.L., Diprete C.C., Ni B.-F., Ehmann W.D., Markesbery W.R. (1995) Elemental imbalances in the olfactory pathway in Alzheimer's disease. J. Neurol. Sci. 130, 139–145.
  • Sayre L.M., Zelasko D.A., Harris P.L., Perry G., Salomon R.G., Smith M.A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68, 2092–2097.
    Direct Link:
  • Sayre L.M., Perry G., Harris P.L., Liu Y., Schubert K.A., Smith M.A. (2000) In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J. Neurochem. 74, 270–279.
    Direct Link:
  • Selkoe D.J. (1998) The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8, 447–453.
  • Shim H. & Harris Z.L. (2003) Genetic defects in copper metabolism. J. Nutr. 133, 1527S–1531S.
  • De Silva D.M. & Aust. S.D. (1993) Ferritin and ceruloplasmin in oxidative damage: review and recent findings. Can. J. Physiol. Pharmacol. 71, 715–720.
  • Smith M.A., Taneda S., Richey P.L. et al. (1994) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl Acad. Sci. USA 91, 5710–5714.
  • Smith M.A., Harris P.L., Sayre L.M., Perry G. (1997) Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94, 9866–9868.
  • Smith M.A., Hirai K., Hsiao K. et al. (1998a) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 70, 2212–2215.
    Direct Link:
  • Smith M.A., Sayre L.M., Anderson V.E. et al. (1998b) Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J. Histochem. Cytochem. 46, 731–735.
  • Smith M.A., Wehr K., Harris P.L., Siedlak S.L., Connor J.R., Perry G. (1998c) Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res. 788, 232–236.
  • Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K., Perry G. (2000) Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502, 139–144.
  • Sparks D.L. & Schreurs B.G. (2003) Trace amounts of copper in water induce {beta}-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc. Natl Acad. Sci. USA.
  • Squitti R., Lupoi D., Pasqualetti P. et al. (2002) Elevation of serum copper levels in Alzheimer's disease. Neurology 59, 1153–1161.
  • Stadtman E.R. & Oliver C.N. (1991) Metal-catalyzed oxidation of proteins. Physiological consequences. J. Biol. Chem. 266, 2005–2008.
  • Sturchler-Pierrat C., Staufenbiel M. (2000) Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann. NY Acad. Sci. 920, 134–139.
    Direct Link:
  • Suh S.W., Jensen K.B., Jensen M.S. et al. (2000) Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 852, 274–278.
  • Syme C.D., Nadal R.C., Rigby S.E., Viles J.H. (2004) Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease. Folding, coordination geometry, pH dependence, stoichiometry and affinity of Abeta (1–28); insights from a range of complementary spectroscopic techniques. J. Biol. Chem. 279, 18169–18177.
  • Takeda A. (2003) Manganese action in brain function. Brain Res. Brain Res. Rev. 41, 79–87.
  • Thomas L.O., Boyko O.B., Anthony D.C., Burger P.C. (1993) MR detection of brain iron. Am. J. Neuroradiol. 14, 1043–1048.
  • Tuppo E.E., Forman L.J., Spur B.W., Chan-Ting R.E., Chopra A., Cavalieri T.A. (2001) Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res. Bull. 54, 565–568.
  • Walsh D.M., Klyubin I., Fadeeva J.V. et al. (2002a) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539.
  • Walsh D.M., Klyubin I., Fadeeva J.V., Rowan M.J., Selkoe D.J. (2002b) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552–557.
  • Wand G.S., May C., May V., Whitehouse P.J., Rapoport S.I., Eipper B.A. (1987) Alzheimer's disease: low levels of peptide alpha-amidation activity in brain and CSF. Neurology 37, 1057–1061.
  • Wang J., Dickson D.W., Trojanowski J.Q., Lee V.M. (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328–337.
  • Wang J., Tanila H., Puolivali J., Kadish I., Van Groen T. (2003) Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 14, 318–327.
  • Wender M., Szczech J., Hoffmann S., Hilczer W. (1992) Electron paramagnetic resonance analysis of heavy metals in the aging human brain. Neuropatol. Pol. 30, 65–72.
  • White A.R., Multhaup G., Maher F. et al. (1999a) The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J. Neurosci. 19, 9170–9179.
  • White A.R., Reyes R., Mercer J.F. et al. (1999b) Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res. 842, 439–444.
  • Whitson J.S., Selkoe D.J., Cotman C.W. (1989) Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science 243, 1488–1490.
  • Whitson J.S., Glabe C.G., Shintani E., Abcar A., Cotman C.W. (1990) Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci. Lett. 110, 319–324.
  • Wong B.S., Chen S.G., Colucci M. et al. (2001) Aberrant metal binding by prion protein in human prion disease. J. Neurochem. 78, 1400–1408.
    Direct Link:
  • Woodward W.D., Filteau S.M., Allen O.B. (1984) Decline in serum zinc level throughout adult life in the laboratory mouse. J. Gerontol. 39, 521–524.
  • Yankner B.A., Duffy L.K., Kirschner D.A. (1990) Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279–282.
  • Yassin M.S., Ekblom J., Xilinas M., Gottfries C.G., Oreland L. (2000) Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J. Neurol. Sci. 173, 40–44.
  • Zecca L., Gallorini M., Schunemann V. et al. (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76, 1766–1773.
    Direct Link:
View Full Article (HTML) Get PDF (210K)